Antiplatelet agents for intermittent claudication (Q24235178)

1

0 references

Lee Yee Chong

2

0 references

Dimitris P Mikhailidis

3

0 references

Peter Robless

Cochrane Database of Systematic Reviews

4

0 references

publication date

9 November 2011

0 references

published in

0 references

cites work

Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A.D.E.P. study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

The STIMS trial: the ticlopidine experience and its clinical applications. Swedish Ticlopidine Multicenter Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

A multicenter prospective randomized trial to determine the optimal treatment of patients with claudication and isolated superficial femoral artery occlusive disease: conservative versus endovascular versus surgical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Long-term evaluation of indobufen in peripheral vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Variability in responsiveness to clopidogrel in patients with intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

A long-term study of policosanol in the treatment of intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Patients with peripheral arterial disease in the CHARISMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

A comparison between aspirin and pentoxifylline in relieving claudication due to peripheral vascular disease in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone--a randomized pilot trial (the PROMPT Study). Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Long term prognosis in patients with peripheral arterial disease treated with antiplatelet agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Comparison of beraprost and ticlopidine in Chinese patients with chronic peripheral arterial occlusion: a multicenter, single-blind, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Platelet survival, atherosclerotic intermittent claudication and ticlopidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

A dose-effect study of beraprost sodium in intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Physical Training and Antiplatelet Treatment in Stage II Peripheral Arterial Occlusive Disease: Alone or Combined?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

A human model of platelet-leucocyte adhesive interactions during controlled ischaemia in patients with peripheral vascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Use of abciximab and tirofiban in patients with peripheral arterial occlusive disease and arterial thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Aspirin in peripheral arterial disease: breakthrough or pitfall?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Effect of ticlopidine on peripheral obliterating arteriopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Design of the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Lipid-lowering for peripheral arterial disease of the lower limb

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Comparison of efficacy of antiplatelet treatments for patients with claudication. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Critical issues in peripheral arterial disease detection and management: a call to action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Mortality over a period of 10 years in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Mortality and morbidity in patients with intermittent claudication in relation to the location of the occlusive atherosclerosis in the leg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Intermittent claudication. Incidence in the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Role of systolic blood pressure and plasma triglycerides in diabetic peripheral arterial disease. The Edinburgh Artery Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Picotamide, an antithromboxane agent, inhibits the migration and proliferation of arterial myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Antiplatelet agents for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Decline in the risk of myocardial infarction among women who stop smoking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Management of Hypertension in Peripheral Arterial Disease: Does the Choice of Drugs Matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

One-year cardiovascular event rates in outpatients with atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Cell adhesion mechanisms in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Exercise for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

A double-blind trial of suloctidil v. Placebo in intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Controlled trial of high-versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Effect of Acetylsalicylic Acid and Dipyridamole on Platelet Survival and Aggregation in Patients with Atherosclerosis Obliterans

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life of patients with intermittent claudication

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Efficacy of indobufen in the treatment of intermittent claudication

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Clinical efficacy of picotamide in long-term treatment of intermittent claudication

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Blood viscosity during long-term treatment with ticlopidine in patients with intermittent claudication. A double-blind study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Three-month therapy with calcium-heparin in comparison with ticlopidine in patients with peripheral arterial occlusive disease at Leriche-Fontaine IIb class

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Hemodynamic, hemorheologic, and hemocoagulative changes after treatment with picotamide in patients affected by peripheral arterial disease (PAD) of the lower limbs

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Long-term effects of ticlopidine on lower limb blood flow, ankle/brachial index and symptoms in peripheral arteriosclerosis. A double-blind study. The STIMS Group in Lund. Swedish Ticlopidine Multicenter Study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Effects of indobufen and pentoxifylline on walking capacity and hemostasis in patients with intermittent claudication: results of six months of treatment

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Treatment of intermittent claudication with antiplatelet agents

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Reliability of treadmill testing in peripheral arterial disease: a comparison of a constant load with a graded load treadmill protocol

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

Medical treatment of intermittent claudication: a comparative double-blind study of suloctidil, dihydroergotoxine and placebo

1 reference

https://api.crossref.org/works/10.1002/14651858.CD001272.PUB2

7 January 2021

10.1002/14651858.CD001272.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_gtlj44gsjnc4xpmctxt3bjpqhy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gtlj44gsjnc4xpmctxt3bjpqhy

24 November 2022